What is novartis

Interesting statistics In the following 5 chapters, you will quickly find the 25 most important statistics relating to "Novartis". Statistics on the topic. Overview Pharmaceutical market: worldwide revenue Novartis' revenue Novartis revenue by segment. Global Rx drug market share by top companies and More interesting topics Related topics. Global pharmaceutical industry. Pharmaceutical industry in the U.

Go to report. Matej Mikulic. Today's High. Today's Low. Shares Out MIL. Market Cap MIL. Latest Developments More. Industry Major Drugs. Contact Info Lichtstrasse 35 Switzerland.

Key Stats 2. Return on Investment TTM. Return on Equity TTM. Latest News Latest News. Novartis may divest generic unit Sandoz as price pressures mount Novartis has raised the prospect of divesting its generic drugs unit Sandoz after years of revamping the business, as price pressures mount in the off-patent drug sector. Novartis lung cancer drug fails another Phase III trial Novartis said on Monday its canakinumab drug had failed in another trial, missing targets to improve overall survival rates for lung cancer patients and prevent the progression-free survival of people with the condition.

Novartis buys gene therapy firm Arctos Medical in vision loss treatment push Swiss drugmaker Novartis said on Tuesday it has bought gene therapy specialist Arctos Medical for an undisclosed amount, aiming to boost its efforts to find treatments for severe vision loss. Novartis halts study of iscalimab in kidney transplant patients Novartis has halted a clinical trial of CFZ iscalimab in kidney transplant patients after interim data showed it was not as good as tacrolimus-based treatment in preventing organ rejection, the Swiss group said on Friday.

While Ciba and Geigy became one, Sandoz continued to advance its pharmaceutical business, introducing anti-allergic drug Zaditen ketotifen in , followed by immunosuppressants Sandimmun cyclosporine in and Neoral cyclosporine in In December , Sandoz and Ciba-Geigy merged to form Novartis in one of the largest corporate mergers in history.

Sandoz remained as a subsidiary of Novartis and today develops, manufactures and markets generic drugs. Today, Sandoz employs over 23, people in countries, with global headquarters based in Holzkirchen, Germany. Vasella was hired by Sandoz back in and remained there until when he was promoted to CEO of its parent company, Sandoz Pharma. He was also on the Board of Directors and was named Chairman in Since its establishment, Novartis has unified and strengthened its global business and research network.

You are now leaving the novartisclinicaltrials. This link will take you to a website to which our Privacy policy does not apply. You are solely responsible for your interactions with that website.

Home Clinical study results Ongoing trials. Eligibility Criteria. Our commitment to share clinical trial data.